Table 2.

AMP SLE Phase 1 Demographic information.

	Cases n=57*	Controls n=15*
Gender
Female	52 (92%)	11 (73%)
Male	5 (9%)	4 (27%)
Race
Asian	7 (12%)	0
Black/African American	23 (40%)	3 (20%)
Unknown or not reported	3 (5%)	1 (7%)
White	25 (43%)	11 (73%)
Ethnicity
Hispanic or Latino	17 (30%)	2 (13%)
Not Hispanic	40 (70%)	13 (87%)
Age at biopsy (years)	31.93 ± 10.50	35.54 ± 6.27
Medication
Belimumab	3 (5%)
Prednisone	39 (68%)
Hydroxychloroquine	51 (89%)
Methotrexate	1 (2%)
Mycophenolic Acid	1 (2%)
Mycophenolate mofetil	14 (25%)
dsDNA+ (n=48)	40 (83%)
Low C3 (n=56)	42 (75%)
Low C4 (n=56)	37 (66%)
ISN Class**
[I]	1 (2%)
[II]	2 (4%)
[II][V]	1 (2%)
[III]	10 (17%)
[III][V]	9 (16%)
[IV]	9 (16%)
[IV][V]	10 (17%)
[V]	15 (26%)
Activity (n=37)	4.69 (SEM: 0.78; Range: 0–16) †
Chronicity (n=37)	1.95 (SEM: 0.29; Range: 0–7) ‡
ACR 1997 Score (n=57)	5.84
SLICC Score (n=51)	7.80
SELENA-SLEDAI (n=57)	12.93
SLICC Damage Index (n=51)	3.99

^*45 LN and 12 LD controls analyzed in Phase 1 and the others rolled over to Phase 2

^**Class VI biopsies were excluded

^†Maximum 24

^‡Maximum 12